Table 1. Demographic and clinicopathological characteristics of patients with stage IV non-small cell lung cancer.
| Characteristics | Anti-PD-1 plus chemotherapy (n=100) | Chemotherapy (n=50) | P value |
|---|---|---|---|
| Age (years), median [range] | 65 [40–84] | 64 [35–77] | 0.13 |
| Gender, n [%] | 0.14 | ||
| Male | 84 [84] | 37 [74] | |
| Female | 16 [16] | 13 [26] | |
| Smoking history, n [%] | 0.09 | ||
| Yes | 77 [77] | 32 [64] | |
| No | 23 [23] | 18 [36] | |
| Histology, n [%] | <0.001 | ||
| Squamous cell carcinoma | 51 [51] | 10 [20] | |
| Adenocarcinoma | 43 [43] | 29 [58] | |
| Others | 6 [6] | 11 [22] | |
| ECOG PS, n [%] | 0.51 | ||
| 0–1 | 86 [86] | 41 [82] | |
| 2–3 | 10 [10] | 6 [12] | |
| Unknown | 4 [4] | 3 [6] | |
| PD-L1 TPS, n [%] | 0.41 | ||
| <1% | 13 [13] | 5 [10] | |
| 1–49% | 15 [15] | 8 [16] | |
| ≥50% | 10 [10] | 2 [4] | |
| Unknown | 62 [62] | 35 [70] | |
| Best disease evaluation, n [%] | <0.001 | ||
| CR + PR | 46 [46] | 7 [14] | |
| SD | 44 [44] | 33 [66] | |
| PD | 10 [10] | 10 [20] | |
| Metastasis, n [%] | |||
| Lung metastasis | 36 [36] | 11 [22] | 0.08 |
| Pleural metastasis | 54 [54] | 24 [48] | 0.49 |
| Abdominal metastasis | 21 [21] | 12 [24] | 0.68 |
| Brain metastasis | 14 [14] | 7 [14] | >0.99 |
| Stage, n [%] | 0.91 | ||
| IVA | 53 [53] | 26 [52] | |
| IVB | 47 [47] | 24 [48] | |
| Platelet (109/L), median [range] | 283.50 [118–623] | 268 [101–473] | 0.46 |
| D-dimer (ng/mL), median [range] | 601.12 [163.07–8,805.71] | 755.34[189.63–>10,000] | 0.13 |
| First-line PD-1 inhibitor, n [%] | NA | NA | |
| Sintilimab | 70 [70] | ||
| Camrelizumab | 4 [4] | ||
| Tislelizumab | 20 [20] | ||
| Pembrolizumab | 6 [6] | ||
| Cycles of first-line PD-1 inhibitor, n [%] | NA | NA | |
| 1–4 | 14 [14] | ||
| 5–35 | 83 [83] | ||
| ≥36 | 3 [3] | ||
| Immunotherapy after chemotherapy, n [%] | NA | NA | |
| Yes | 26 [52] | ||
| No | 24 [48] | ||
PD-1, programmed death protein 1; ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death ligand 1; TPS, tumor proportion score; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not available.